Argentum Pharmaceuticals Succeeds in Starting Patent Cancellatio - Erie News Now | WICU & WSEE in Erie, PA

Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against Novartis' AFINITOR®

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

SOURCE Argentum Pharmaceuticals

NEW YORK, Sept. 29, 2017 /PRNewswire/ -- The U.S. Patent & Trademark Office (PTO) on September 25, 2017 granted Argentum Pharmaceuticals LLC's petition for inter partes review (IPR) against all claims of the last-expiring patent listed as covering Novartis Pharmaceuticals' AFINITOR® (everolimus tablet) drug in the Food & Drug Administration's Orange Book.  Argentum challenges claims 1-3 of Novartis' U.S. Patent No. 9,006,224, which the Orange Book states will expire in 2028.  The PTO concluded that Argentum has established a "reasonable likelihood that [Argentum] would prevail with respect to claims 1–3" of the patent.  The decision marks the beginning of an IPR trial that will be conducted by three specialist patent judges within the PTO's Patent Trial & Appeal Board.  A final decision on patentability in the IPR is due within 1 year.

Argentum Pharmaceuticals. Balancing the rights of pharmaceutical innovators and consumers. (PRNewsFoto/Argentum Pharmaceuticals)

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.  http://www.argentumpharmaceuticals.com

View original content with multimedia:http://www.prnewswire.com/news-releases/argentum-pharmaceuticals-succeeds-in-starting-patent-cancellation-trial-against-novartis-afinitor-300528429.html

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
WICU FCC Filing
WSEE FCC Filing
Share:
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2017 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 - info@wicu12.com